RT Journal Article
SR Electronic
T1 Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5775
OP 5783
DO 10.21873/anticanres.15394
VO 41
IS 11
A1 OMIYA, SATOSHI
A1 KOMATSU, SHOHEI
A1 KIDO, MASAHIRO
A1 KURAMITSU, KAORI
A1 GON, HIDETOSHI
A1 FUKUSHIMA, KENJI
A1 URADE, TAKESHI
A1 SO, SHINICHI
A1 SOFUE, KEITARO
A1 YANO, YOSHIHIKO
A1 SAKAI, YOSHITADA
A1 YANAGIMOTO, HIROAKI
A1 TOYAMA, HIROCHIKA
A1 AJIKI, TETSUO
A1 FUKUMOTO, TAKUMI
YR 2021
UL http://ar.iiarjournals.org/content/41/11/5775.abstract
AB Background/Aim: Sarcopenia has been reported to be a significant prognostic factor in patients with hepatocellular carcinoma in recent years. This study aimed to clarify the prognostic significance of sarcopenia in advanced hepatocellular carcinoma treated with reductive hepatectomy. Patients and Methods: We retrospectively analyzed 93 patients who underwent reductive hepatectomy for advanced hepatocellular carcinoma. Results: Median survival time of the sarcopenia group (16.4 months) was significantly shorter than that of the non-sarcopenia group (20.4 months). The overall survival rates at 1, 3, and 5 years of the sarcopenia group were significantly lower than those of the non-sarcopenia group (57.9%, 8.6%, and 2.9% vs. 67.3%, 29.2%, and 15.7%, respectively; p=0.035). On multivariate analysis, sarcopenia was a significant risk factor of overall survival (hazard ratio=1.60, 95% confidence interval=1.00-2.56, p=0.049). Conclusion: Sarcopenia was a significant prognostic factor of survival after reductive hepatectomy in advanced hepatocellular carcinoma.